Addex Therapeutics (FRA:APE) Gross Profit: €0.03 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Addex Therapeutics Gross Profit?

Addex Therapeutics FRA:APE -2.47% Gross Profit is €0.03 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Addex Therapeutics's gross profit for the three months ended in Mar. 2026 was €0.00 Mil. Addex Therapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Addex Therapeutics's gross profit for the three months ended in Mar. 2026 was €0.00 Mil. Addex Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Addex Therapeutics's Gross Margin % for the quarter that ended in Mar. 2026 was N/A%.

Addex Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage

Addex Therapeutics  (FRA:APE) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Addex Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage

Addex Therapeutics Gross Profit Related Terms

Addex Therapeutics Gross Profit Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Gross Profit Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.80 1.44 1.71 0.43 0.03

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.03 0.00 0.00

FRA:APE vs VRTX, REGN, RVMD: Gross Profit Comparison

For the Biotechnology subindustry, Addex Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics Gross Profit vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Gross Profit falls into.


Addex Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Addex Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2025 is calculated as

Gross Profit (A: Dec. 2025 )=Revenue - Cost of Goods Sold
=0.032 - 0
=0.03

Addex Therapeutics's Gross Profit for the quarter that ended in Mar. 2026 is calculated as

Gross Profit (Q: Mar. 2026 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Addex Therapeutics's Gross Margin % for the quarter that ended in Mar. 2026 is calculated as

Gross Margin % (Q: Mar. 2026 )=Gross Profit (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Profit →
What does a Gross Profit of €0.03 Mil mean?
Addex Therapeutics (FRA:APE) has a Gross Profit of €0.03 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' Gross Profit too high?
Addex Therapeutics' current Gross Profit is €0.03 Mil.
How does Addex Therapeutics' Gross Profit compare to VRTX and REGN?
Addex Therapeutics' Gross Profit of €0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Gross Profit is €0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE) has a current Gross Profit of €0.03 Mil. The current Gross Profit is €0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current Gross Profit is €0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.